Targeting EP4 Receptor in Cancer to Overcome Immunosuppression: DT-9081 an Oral Small Molecule Phase 2 Ready Therapeutic For Solid Tumors
- Presenting Phase 1 outcomes, including safety data, dose-escalation results and the establishment of the Phase 2 dosing regimen
- Highlighting our translational biomarker strategy, including target-engagement readouts and how these biomarkers support Phase 2 readiness
- Outlining the Phase 2 clinical plan in sarcoma, detailing study rationale and how PK/PD and exposure–response insights inform the development approach